Federated Hermes’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Federated Hermes’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-98	Closed	-$1.19K	–	2267
2023 Q1	$1.19K	Sell	98 -119	-55%	-$1.24K	﹤0.01%	2033
2022 Q4	$986	Sell	217 -112	-34%	-$639	﹤0.01%	2055
2022 Q3	$2K	Sell	329 -30	-8%	-$274	﹤0.01%	1999
2022 Q2	$4K	Buy	359 +67	+23%	+$901	﹤0.01%	1927
2022 Q1	$6K	Buy	292 +148	+103%	+$3.3K	﹤0.01%	1947
2021 Q4	$5K	Buy	+144	New	+$8.2K	﹤0.01%	2000

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes's SGTX Position: Q2 2023 in Review

Federated Hermes sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 98 shares — an estimated $1.19K sold.

Federated Hermes first reported a position in SGTX in Q4 2021 and held it in 6 quarters. The position peaked at $6K in Q1 2022. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Federated Hermes reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Federated Hermes sold 98 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.19K.
Federated Hermes first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Federated Hermes's Sigilon Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2022.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.